Salvianolic acid A inhibits the growth of diffuse large B-cell lymphoma through MAPK pathways

Diffuse large B-cell lymphoma (DLBCL), an immense heterogeneous disease, can be categorized into two major molecular subtypes termed germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL [1]. This molecular distinction represents lymphomas derivating from different stages of B cell differentiation, and reflects fairly different intracellular oncogenic pathways for pathogenesis [2-4]. Although the combinatorial chemotherapy R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) makes the majority of patients curable [5], a subset exhibits severe side effects or relapses after initial treatment.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research